TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00782340
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
Study: NCT01362140
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by subcutaneous injection every 3 weeks
Study: NCT03446443
Drug: Honghe Fujie lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Before application，wash the vaginal area with water and dry it. Take10ml Hong He Fujie into dilution bottles，added to 100ml with warm boiled water, using diluted lotion for the rinse of vulva and vagina, twice daily for 7days.
Study: NCT02428868
Drug: intravenous iron (Ferroven®)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 vials of 10 mL containing each one 100 mg iron, diluted in 100 mL normal saline over 30 minutes before induction of anesthesia and repeated on day two and three.
Study: NCT01265069
Drug: concomitant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: rabeprazole 20 mg,amoxicillin 1000 mg,metronidazole 500 mg,clarithromycin 500 mg, bid for 10 days
Study: NCT00250887
Drug: Gefitnib
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01357798
Drug: 0,9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0,9% saline group Will have the syringe with 0,9% saline. During the study the patients will be following in the headache's clinic where the evaluator will graduate the pathologies' evolution .
Study: NCT03793985
Drug: R
Normalized name: R
Approvals — FDA: no, EMA: no, PMDA: no
Description: D086 and D337 co-administration
Study: NCT03560427
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive placebo tablet 2 hour before operation and will be anesthetized by combined spinal-general anesthesia that includes: spinal anesthesia with morphine 0.3 mg delivered in L4-5 inter spinous space.~General anethseia: Induction of anesthesia was done by intravenous fentanyl, 2 µg / kg and propofol 1 - 2 mg / kg. Endotracheal intubation was achieved by cis-atracurium, 0.15 mg / kg. Maintenance of anesthesia was done by isoflurane and cis-atracurium, 0.03 mg / kg on demand. Additional intraoperative analgesia was consisted of administration of intravenous boluses of fentanyl, 50 µg according to the attending anesthesiologist's decision. At the end of surgery, muscle relaxation was reversed using neostigmine 0.05 mg / kg and atropine 0.01 mg / kg.
Study: NCT02415400
Drug: vitamin K antagonist
Normalized name: Vitamin K antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02415400
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00395876
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL of placebo instilled into lumen of dysfunctional CVC. Patients weighing ≥ 30 kg received 2-mL instillations of study drug (i.e., 2 mg of placebo). Patients weighing \< 30 kg received instillations of study drug equal to 110% of the internal lumen volume of the dysfunctional CVC. This dose was rounded to the nearest 0.1 mL and should not have exceeded 2 mL (2 mg).
Study: NCT00604253
Drug: insulin NPH
Normalized name: insulin NPH human isophane
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05216172
Drug: AZD1656
Approvals — FDA: no, EMA: no, PMDA: no
Description: active drug
Study: NCT05216172
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT03564912
Drug: Capecitabine Oral Tablet [Xeloda]
Normalized name: capecitabine Oral Tablet [Xeloda]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 week group: capecitabine 1000mg/m2 d1-10; oxaliplatin 85mg/m2; q2w 3 week group: capecitabine 1000mg/m2 d1-14; oxaliplatin 130mg/m2; q3w
Study: NCT00167544
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone 3 mg/kg/d divided q 12h IV/PO tapered over 7 days
Study: NCT00167544
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline
Study: NCT00126516
Drug: Angiotensin-converting Enzyme Inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: any dosage, frequency, and duration
Study: NCT04458948
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin 500 mg, IV or po for 5 days
Study: NCT02440958
Drug: modified FOLFIRINOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified FOLFIRINOX regimen consisted of oxaliplatin at a dose of 60 mg per square meter, given as a 2-hour intravenous infusion, after 60 minutes, of irinotecan at a dose of 120 mg per square meter, given as a 90-minute intravenous infusion, immediately followed by leucovorin at a dose of 400 mg per square meter, given as a 2-hour intravenous infusion through a Y-connector. This treatment was immediately followed by fluorouracil at a dose of 400 mg per square meter, administered by intravenous bolus, followed by a continuous intravenous infusion of 2400 mg per square meter over a 46-hour period every 2 weeks
Study: NCT00868023
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00647868
Drug: testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal testosterone, 7.6 mg (3.8 mg in each nostril) per application
Study: NCT03719326
Drug: Pegylated liposomal doxorubicin (PLD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxil is an anthracycline topoisomerase II inhibitor that is encapsulated in liposomes for intravenous (IV) use
Study: NCT00875836
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flexible dose, up to 60 mg daily
Study: NCT01140191
Drug: WR 279,396
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of WR 279,396 cream (15% paromomycin + 0.5% gentamicin)once daily for 20 days
Study: NCT00549926
Drug: Fluvastatin
Normalized name: Fluvastatin
DrugBank: Fluvastatin (DB01095)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00549926
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00981591
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled via Aerogen nebulizer, 0.5 mcg/kg every 2 hours or more
Study: NCT03095521
Drug: ANTI-ANGIN® FORMULA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0,2 mg + 2 mg + 50 mg (LLC Valeant, Russia). Administered per 1 lozenge, with an interval 2 hours or more, up to 6 lozenges per day, for a maximum 5 days or until full illness resolution.
Study: NCT00755846
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin placebo-matching tablets, orally, once daily for up to 12 weeks.
Study: NCT01711320
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03444818
Drug: [14C]-E6007
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT00124527
Drug: Irofulven + capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01650259
Drug: OAD
Normalized name: Toad toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAD except Trazenta tablets
Study: NCT02389712
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine dosing: 20mg for month 1, 40mg for month 2, and if still depressed (CGI ≥ 3) 60mg for month 3 and 4. Lower doses of fluoxetine will be prescribed for those with side effects. For known Cytochrome P450 2D6 poor metabolizers, fluoxetine will not be dosed \> 40mg.
Study: NCT00444509
Drug: GW685698X
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW685698X will available with a unit dose strength of 400 mcg that will be inhaled via DISKUS
Study: NCT03746223
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400ug intravitreal injection every week for 4 doses in the induction phase, every 2 weeks for 2 doses as consolidation, then every month for 10 doses as maintenance
Study: NCT03349450
Drug: Cyclophosphamide 50mg
Normalized name: CYCLOPHOSPHAMIDE 50MG TAB
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 50mg twice daily by mouth, administered 7 days on / 7 days off, stating at study day 0, until study day 384
Study: NCT00936858
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01289912
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAD001 is formulated as tablets of 5.0 mg strength, blister-packed under aluminum foil in units of 10 tablets and dosed on a regular basis. RAD001 tablets should be opened only at the time of administration as drug is both hygroscopic and light-sensitive.~Patients will be instructed to take 4.5 mg/m2 of RAD001 orally with a glass of water at regular intervals at the same time in the morning after a light, nonfat breakfast.
Study: NCT01289912
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be provided as a matching tablet and will also be blister packed under aluminum foil in units of 10. Matching placebo tablets should be opened only at the time of administration as drug is both hygroscopic and light-sensitive.~Patients will be instructed to take 4.5 mg/m2 of the matching placebo orally with a glass of water at regular intervals at the same time in the morning after a light, nonfat breakfast.
Study: NCT00092131
Drug: Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet administered orally as a single witnessed dose before exercise challenge
Study: NCT03835533
Drug: NKTR-214 (Cohort A)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NKTR-214 will be administered intravenously every 3 weeks for up to 2 years
Study: NCT03348254
Drug: Single shot antibiotic prophylaxis
Normalized name: ChoreMate One-Shot
Approvals — FDA: no, EMA: no, PMDA: no
Description: single shot preoperative antibiotic prophylaxis
Study: NCT03348254
Drug: Multiple shot antibiotic prophylaxis
Normalized name: ChoreMate One-Shot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple shot perioperative antibiotic prophylaxis
Study: NCT02372409
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01383538
Drug: FOLFIRINOX, IPI-926
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin: intravenous, 50 to 85 mg/m2, over 2 hrs, once per cycle.~Leucovorin: intravenous, 400 mg/m2, over 2 hrs, once per cycle.~Irinotecan: intravenous, 120 to 180 mg/m2, over 90 minutes, once per cycle.~5-FU: intravenous, 1600 to 2400mg/m2, over 46hr continuous infusion, once per cycle.~IPI-926: oral, 130 to 160 mg/day, daily, 14 days per cycle.
Study: NCT01660763
Drug: Sufentanil NanoTab PCA System/15 mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mcg Sufentanil NanoTab dosed sublingually every 20 minutes as needed for pain for at least 48 hours. Patients may elect to remain in study for up to 72 hours.
Study: NCT01660763
Drug: Placebo Sufentanil NanoTab PCA System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo NanoTab dosed sublingually every 20 minutes as needed for pain for at least 48 hours. Patients may elect to remain in study for up to 72 hours.
Study: NCT00078559
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 650 mg may be given 30-60 minutes prior to start of each infusion of alemtuzumab to prevent infusion related side effects such as fever, skin rash and pruritis
Study: NCT01813240
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01813240
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01024322
Drug: Ciprofloxicine or Vigamox or other.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxicine or Vigamox or other to be used qid till epithelialized.
Study: NCT01024322
Drug: Steroid (FML, Pred Forte, Flarex, etc.)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid (FML, Pred Forte, Flarex, etc.) to be used qid for 8 weeks.
Study: NCT04223193
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo matching to tavapadon QD orally for 27 weeks.
Study: NCT01311102
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.33cc normal saline
Study: NCT02276300
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Treatment of mild Endoxan application three days before Her2 vaccination
Study: NCT04377646
Drug: Zinc
Normalized name: Zinc
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 15 mg per day up to 2 months
Study: NCT04377646
Drug: Zinc (Placebo)
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 pill per day up to 2 months
Study: NCT01011010
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TACE (day 18-20): Doxorubicin 50mg and mitomycin C 10mg mixed with lipoidal and injected in proportion to liver volume being treated, followed by embospheres. Administered until there is a pruned tree appearance on angiography. If a second TACE is to be performed it should be performed within 8 weeks of the first procedure.
Study: NCT02182193
Drug: BIBF 1120 drinking solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00768274
Drug: RVX000222
Approvals — FDA: no, EMA: no, PMDA: no
Description: RVX000222 twice daily (b.i.d.) for 28 days
Study: NCT00768274
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice daily (b.i.d.) for 28 days
Study: NCT02446561
Drug: MRXXX
Normalized name: I'm afraid I don't have enough information to determine the full generic name for the drug abbreviation 'MRXXX'. Drug abbreviations can vary and may not be standardized, so without more context about the specific drug or clinical trial, I cannot provide the full generic name. If you have additional details about the drug or trial, please provide that information, and I'll do my best to look up the full generic name.
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02446561
Drug: MR1XXX
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02446561
Drug: MR2XXX
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02446561
Drug: MR3XXX
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02142049
Drug: DA-EPOCH-R
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoposide, Prednisone, Doxorubicin, Cyclophosphamide, Vincristine, Rituximab, Pegfilgrastim
Study: NCT00864448
Drug: Atlace® 10 mg capsules, single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: B: Active comparator Subjects received Monarch Pharmaceuticals Inc. formulated products under fasting conditions
Study: NCT00778674
Drug: Benazepril HCl/ Hydrochlorothiazide 20 mg/ 25 mg Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00149253
Drug: a single-dose of Etoricoxib before induction of anesthesia
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04706468
Drug: TG-1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules taken orally
Study: NCT02491008
Drug: Levothyroxine
Normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects \<50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is \<0.4 mU/L, dose will be reduced by 25 mcg; TSH \>=0.4 and \<4.6 mU/L, no change to dose; TSH \>=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
Study: NCT02491008
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.~Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg.
Study: NCT04666168
Drug: Cyclophosphamide,Fludarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Cyclophosphamide,Fludarabine
Study: NCT00424528
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo inhalation solution and placebo inhalation powder
Study: NCT01159626
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral single dose as matching placebo
Study: NCT01757756
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo administered twice daily for 14 days
Study: NCT03466333
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo will be encapsulated; participants will take the drug once a day for 6 months following delivery. It will be identical in appearance to the IMP.
Study: NCT01512225
Drug: Placebo Tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablet 10 mg orally three times daily for 14 days
Study: NCT00360308
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01126593
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo group will receive the same subacromial infusion catheter however, the reservoir will be filled with 200cc of 0.9% Normal Saline.
Study: NCT03830034
Drug: Amino Acid chelated iron tab 15 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contain 75 pregnant women will recommended to take ferrotrone(iron chelated amino acid containing 15mg elemental iron) a dose recommended by the company of the product.~Iron tablets should be taken at night or at least 1 hour prior to food to maximise absorption.~Substances that inhibit absorption such as tannins \& milk should be avoided but fruit juice contain ascorbic acid taken in conjunction with iron supplements increases their absorption.~Follow up will be done for all the pregnant women included in our studies at baseline \& then 4, 8 \& 12 weeks after treatment at each visit breif history for outcomes and adverse effects will reviewed.
Study: NCT01227681
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium Chloride (NaCl) 0.9 %
Study: NCT01091324
Drug: Silymarin
Normalized name: silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg , tid
Study: NCT03398005
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 x 1 g capsules administered orally once a day for 26 weeks
Study: NCT00152776
Drug: ovaria comp 10 globuli 3 times per day 24 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Description: order of intervention and placebo varies between Groups I-III
Study: NCT01569516
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0mg, tid
Study: NCT04255160
Drug: Estradiol (mylan or vivelle dot patch)
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (0.1mg/day patch) will be used by women for 7 days. Administration of the patch will follow the package guidelines to change the patch after 3-4 days of use.
Study: NCT02575092
Drug: Enalapril Maleate and Folic Acid tablets(as the program-based antihypertension)
Normalized name: Enalapril Maleate
DrugBank: Enalapril (DB00584)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02575092
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02508311
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive placebo tablets twice daily for 16 weeks.
Study: NCT00849251
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV or PO
Study: NCT00849251
Drug: pegylated liposomal doxorubicin hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT01906294
Drug: antidiabetic treatment (ATC A10B)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01850680
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:solution Route of administration: subcutaneous
Study: NCT01850680
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form:capsule Route of administration: oral
Study: NCT01850680
Drug: folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form:tablet Route of administration: oral
Study: NCT02702518
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug vehicle 4 times a day for 8 weeks
Study: NCT01512862
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage of 0.25 mcg administered orally once daily for 6 weeks and dose escalated to 0.5 mcg orally once daily up to 6 months
Study: NCT00868439
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT02347761
Drug: Placebo BID eFlow Closed System (CS) nebulizer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice daily (BID) eFlow Closed System (CS) nebulizer
Study: NCT00001430
Drug: EPOCH II
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02995772
Drug: Aromatase Inhibitors (Arimidex)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of efficacy with chemotherapy
Study: NCT02995772
Drug: Aromatase Inhibitors (Femara)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of efficacy with chemotherapy
Study: NCT02995772
Drug: Aromatase Inhibitors (Aromasin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of efficacy with chemotherapy
Study: NCT04301336
Drug: Vit D
Normalized name: Tri-Vit Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 patients from each participating hospital that will receive Vit-D medication (1500 IU to 3500 IU ) per day for 8 consecutive months up to 10 months.~in addition to the experimental treatment, this group will receive the traditional treatment of hydroxyurea, Folic acid, pain killer plus regular blood transfusion with a dose de-escalation methods till efficacy of experimental treatment proved.